ReviewBest practice & research. Clinical obstetrics & gynaecology2015
Molecular staging of gynecological cancer: What is the future?
Review in Best practice & research. Clinical obstetrics & gynaecology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Integration of machine learning and bulk sequencing revealed exosome-related gene FOSB was involved in the progression of abdominal aortic aneurysm.Frontiers in cell and developmental biology · 2025Article
- Molecular Signatures of Gynecological Cancers: Clinicians Perspective.Indian journal of surgical oncology · 2021Review
- Predicting high-risk endometrioid carcinomas using proteins.Oncotarget · 2018Article
- The Complementary Role of Imaging and Tumor Biomarkers in Gynecological Cancers: An Update of the LiteratureAsian Pacific journal of cancer prevention : APJCP · 2018Review
- The Importance of Steroid Uptake and Intracrine Action in Endometrial and Ovarian Cancers.Frontiers in pharmacology · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The purpose of cancer staging is to classify cancers into prognostic groups and to allow for comparison of treatment results and survival between patients and institutions. Staging for gynecologic cancers is based on extent of disease and metastasis, which was historically determined by physical examination and is now based on surgical and histologic examination of tumor specimens. Although the extent of disease is currently considered the most important predictor of recurrence and survival, current staging does not include molecular features that are associated with tumor aggressiveness, response to therapy, and prognosis. This review focuses on genomic and proteomic features of gynecologic cancers and the future of biomarkers in staging classification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.